The impact of atrial fibrillation type on clinical outcomes and antithrombotic therapy at discharge in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a real-world study

Abstract Background The type of atrial fibrillation (AF) is assumed as a vital factor in AF patients’ prognosis. However, its impact on clinical outcomes remains unclear in patients with AF complicated with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI). Methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Yimeng Wang, Jingyang Wang, Yuyuan Shu, Yijing Xin, Yanmin Yang
Format: Article
Language:English
Published: BMC 2025-08-01
Series:BMC Cardiovascular Disorders
Subjects:
Online Access:https://doi.org/10.1186/s12872-025-05042-7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849767521164460032
author Yimeng Wang
Jingyang Wang
Yuyuan Shu
Yijing Xin
Yanmin Yang
author_facet Yimeng Wang
Jingyang Wang
Yuyuan Shu
Yijing Xin
Yanmin Yang
author_sort Yimeng Wang
collection DOAJ
description Abstract Background The type of atrial fibrillation (AF) is assumed as a vital factor in AF patients’ prognosis. However, its impact on clinical outcomes remains unclear in patients with AF complicated with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI). Methods This study was a prospective, observational, single center study of adults with AF and ACS/PCI. The primary endpoint was major adverse cardiovascular events (MACE), and secondary endpoint was net adverse clinical outcome events (NACE), a composite of MACE events and major bleeding events. Results A total of 1,762 participants were enrolled in this study, 1,137 of them were paroxysmal AF and 625 were non- paroxysmal AF, with a median follow up time of 1,023 days. The mean age of this population was 67 ± 10 and 27.2% were female. Kaplan–Meier curves showed patients were under a higher incidence of both MACE (p < 0.001) and NACE (p < 0.001) in patients with non-paroxysmal AF. Multivariate Cox analysis showed that patients with non-paroxysmal AF had a higher risk of MACE (HR: 1.322; 95%CI 1.074–1.626) and NACE (HR: 1.341; 95%CI 1.095–1.644) compared to those with paroxysmal AF. Conclusions Our study demonstrated that among patients with ACS/PCI, those with non-paroxysmal AF were more likely to experience MACE and NACE.
format Article
id doaj-art-1af34cdcefaf4a9d98d74a3bd2faecad
institution DOAJ
issn 1471-2261
language English
publishDate 2025-08-01
publisher BMC
record_format Article
series BMC Cardiovascular Disorders
spelling doaj-art-1af34cdcefaf4a9d98d74a3bd2faecad2025-08-20T03:04:10ZengBMCBMC Cardiovascular Disorders1471-22612025-08-012511810.1186/s12872-025-05042-7The impact of atrial fibrillation type on clinical outcomes and antithrombotic therapy at discharge in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a real-world studyYimeng Wang0Jingyang Wang1Yuyuan Shu2Yijing Xin3Yanmin Yang4Emergency and Intensive Care Center, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeEmergency and Intensive Care Center, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeEmergency and Intensive Care Center, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeEmergency and Intensive Care Center, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeEmergency and Intensive Care Center, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Background The type of atrial fibrillation (AF) is assumed as a vital factor in AF patients’ prognosis. However, its impact on clinical outcomes remains unclear in patients with AF complicated with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI). Methods This study was a prospective, observational, single center study of adults with AF and ACS/PCI. The primary endpoint was major adverse cardiovascular events (MACE), and secondary endpoint was net adverse clinical outcome events (NACE), a composite of MACE events and major bleeding events. Results A total of 1,762 participants were enrolled in this study, 1,137 of them were paroxysmal AF and 625 were non- paroxysmal AF, with a median follow up time of 1,023 days. The mean age of this population was 67 ± 10 and 27.2% were female. Kaplan–Meier curves showed patients were under a higher incidence of both MACE (p < 0.001) and NACE (p < 0.001) in patients with non-paroxysmal AF. Multivariate Cox analysis showed that patients with non-paroxysmal AF had a higher risk of MACE (HR: 1.322; 95%CI 1.074–1.626) and NACE (HR: 1.341; 95%CI 1.095–1.644) compared to those with paroxysmal AF. Conclusions Our study demonstrated that among patients with ACS/PCI, those with non-paroxysmal AF were more likely to experience MACE and NACE.https://doi.org/10.1186/s12872-025-05042-7Atrial fibrillation typeAcute coronary syndromePercutaneous coronary interventionCardiovascular adverse events
spellingShingle Yimeng Wang
Jingyang Wang
Yuyuan Shu
Yijing Xin
Yanmin Yang
The impact of atrial fibrillation type on clinical outcomes and antithrombotic therapy at discharge in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a real-world study
BMC Cardiovascular Disorders
Atrial fibrillation type
Acute coronary syndrome
Percutaneous coronary intervention
Cardiovascular adverse events
title The impact of atrial fibrillation type on clinical outcomes and antithrombotic therapy at discharge in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a real-world study
title_full The impact of atrial fibrillation type on clinical outcomes and antithrombotic therapy at discharge in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a real-world study
title_fullStr The impact of atrial fibrillation type on clinical outcomes and antithrombotic therapy at discharge in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a real-world study
title_full_unstemmed The impact of atrial fibrillation type on clinical outcomes and antithrombotic therapy at discharge in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a real-world study
title_short The impact of atrial fibrillation type on clinical outcomes and antithrombotic therapy at discharge in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a real-world study
title_sort impact of atrial fibrillation type on clinical outcomes and antithrombotic therapy at discharge in patients with acute coronary syndrome or undergoing percutaneous coronary intervention a real world study
topic Atrial fibrillation type
Acute coronary syndrome
Percutaneous coronary intervention
Cardiovascular adverse events
url https://doi.org/10.1186/s12872-025-05042-7
work_keys_str_mv AT yimengwang theimpactofatrialfibrillationtypeonclinicaloutcomesandantithrombotictherapyatdischargeinpatientswithacutecoronarysyndromeorundergoingpercutaneouscoronaryinterventionarealworldstudy
AT jingyangwang theimpactofatrialfibrillationtypeonclinicaloutcomesandantithrombotictherapyatdischargeinpatientswithacutecoronarysyndromeorundergoingpercutaneouscoronaryinterventionarealworldstudy
AT yuyuanshu theimpactofatrialfibrillationtypeonclinicaloutcomesandantithrombotictherapyatdischargeinpatientswithacutecoronarysyndromeorundergoingpercutaneouscoronaryinterventionarealworldstudy
AT yijingxin theimpactofatrialfibrillationtypeonclinicaloutcomesandantithrombotictherapyatdischargeinpatientswithacutecoronarysyndromeorundergoingpercutaneouscoronaryinterventionarealworldstudy
AT yanminyang theimpactofatrialfibrillationtypeonclinicaloutcomesandantithrombotictherapyatdischargeinpatientswithacutecoronarysyndromeorundergoingpercutaneouscoronaryinterventionarealworldstudy
AT yimengwang impactofatrialfibrillationtypeonclinicaloutcomesandantithrombotictherapyatdischargeinpatientswithacutecoronarysyndromeorundergoingpercutaneouscoronaryinterventionarealworldstudy
AT jingyangwang impactofatrialfibrillationtypeonclinicaloutcomesandantithrombotictherapyatdischargeinpatientswithacutecoronarysyndromeorundergoingpercutaneouscoronaryinterventionarealworldstudy
AT yuyuanshu impactofatrialfibrillationtypeonclinicaloutcomesandantithrombotictherapyatdischargeinpatientswithacutecoronarysyndromeorundergoingpercutaneouscoronaryinterventionarealworldstudy
AT yijingxin impactofatrialfibrillationtypeonclinicaloutcomesandantithrombotictherapyatdischargeinpatientswithacutecoronarysyndromeorundergoingpercutaneouscoronaryinterventionarealworldstudy
AT yanminyang impactofatrialfibrillationtypeonclinicaloutcomesandantithrombotictherapyatdischargeinpatientswithacutecoronarysyndromeorundergoingpercutaneouscoronaryinterventionarealworldstudy